Clifford Chance, Skadden, Arps, Slate, Meagher & Flom and Justin Chow & Co. Solicitors have advised New York-listed Hong Kong investment firm AMTD on its secondary listing on the Singapore Exchange (SGX), with Kirkland & Ellis advising the underwriters .

AMTD International is the first company to be dual-listed on the New York Stock Exchange (NYSE) and the SGX, as well as the first company with dual-class shares to be listed on the SGX. It is also the first online listing on the SGX.

AMTD listed on the NYSE last year, with Skadden and Kirkland playing roles in that deal.

The Clifford Chance team was led by Raymond Tong.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

Haiwen, CC advise on China TCM's $2 bln take-private deal

by Hu Yangxiaoxiao 胡阳潇潇 |

Sinopharm Group, an investment consortium led by Sinopharm Group, and China Traditional Chinese Medicine Holdings (China TCM) recently announced a take-private deal for the Hong Kong-listed China TCM through a scheme of arrangement.

Deals

CC, Davis Polk act on ChaPanda’s $330 mln Hong Kong IPO

by Charlie Wu 吴卓言 |

Davis Polk & Wardwell and Jingtian & Gongcheng have advised Sichuan Baicha Baidao, a Chinese low-priced tea chain also known as ChaPanda, on its $330 million IPO on the Hong Kong Stock Exchange, with Clifford Chance and King & Wood Mallesons acting for the sponsor CICC and underwriters.

Deals

CC, Slaughters advise as HK-listed SciClone goes private for $1.13 bln

by Hu Yangxiaoxiao 胡阳潇潇 |

Clifford Chance has advised the Hong Kong-listed SciClone Pharmaceuticals on an offer to take it private by healthcare-focused private equity firm GL Capital, with Slaughter and May acting for the buyer’s financial adviser, Capital Corporation Hong Kong Securities (CICC).